68 related articles for article (PubMed ID: 24632756)
1. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Qiu YQ; Zhou J; Kang XS; Ding LM; Yu W; Tan FL; Deng DF
Sci Rep; 2014 Mar; 4():4324. PubMed ID: 24632756
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
Wu L; Zhou J; Zhou W; Huang XF; Chen Q; Wang W; Zhai L; Li S; Tang Z
Pathol Res Pract; 2021 Apr; 220():153270. PubMed ID: 33640712
[TBL] [Abstract][Full Text] [Related]
3. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
6. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Zhang Y; Zhang B; Zhang A; Zhao Y; Zhao J; Liu J; Gao J; Fang D; Rao Z
Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
[TBL] [Abstract][Full Text] [Related]
7. Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.
Giovannini C; Baglioni M; Baron Toaldo M; Cescon M; Bolondi L; Gramantieri L
Sci Rep; 2017 Mar; 7():44685. PubMed ID: 28322221
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
[TBL] [Abstract][Full Text] [Related]
10. [The influence of knocking down the expression of low-density lipoprotein receptor associated proteins on the vascular abnormalities in hepatocellular carcinoma and its mechanisms].
Wu Q; Zhan LL; Wang Y; He YC; Chen L; Chen ZZ; Li GT; Liu DM; Bao X; Liu XM; Guo H; Song TQ
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):399-408. PubMed ID: 38742353
[No Abstract] [Full Text] [Related]
11. Combination of Astragali Polysaccharide and Curcumin Improves the Morphological Structure of Tumor Vessels and Induces Tumor Vascular Normalization to Inhibit the Growth of Hepatocellular Carcinoma.
Tang D; Zhang S; Shi X; Wu J; Yin G; Tan X; Liu F; Wu X; Du X
Integr Cancer Ther; 2019; 18():1534735418824408. PubMed ID: 30762443
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.
Qiu Y; Che B; Zhang W; Zhang AV; Ge J; Du D; Li J; Peng X; Shao J
J Adv Res; 2024 May; 59():97-109. PubMed ID: 37328057
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-Targeted Microbubble Destruction Enhances Inhibitory Effect of Apatinib on Angiogenesis in Triple Negative Breast Carcinoma Xenografts.
Hong D; Yang J; Guo J; Zhang Y; Chen Z
Anal Cell Pathol (Amst); 2021; 2021():8837950. PubMed ID: 33959473
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.
Sinha S; Pal K; Elkhanany A; Dutta S; Cao Y; Mondal G; Iyer S; Somasundaram V; Couch FJ; Shridhar V; Bhattacharya R; Mukhopadhyay D; Srinivas P
Int J Cancer; 2013 Mar; 132(5):1201-12. PubMed ID: 22806981
[TBL] [Abstract][Full Text] [Related]
15. Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma.
Liu S; Wei Y; Nie L; Tang Z; Lu Q; Liang Q
BMC Cancer; 2024 May; 24(1):614. PubMed ID: 38773427
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.
Wang ZM; Zhang SL; Yang H; Zhuang RY; Guo X; Tong HX; Zhang Y; Lu WQ; Zhou YH
Cancer Med; 2020 May; 9(10):3344-3352. PubMed ID: 32181596
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts.
Xin H; Wang K; Hu G; Xie F; Ouyang K; Tang X; Wang M; Wen D; Zhu Y; Qin X
PLoS One; 2014; 9(1):e85308. PubMed ID: 24416385
[TBL] [Abstract][Full Text] [Related]
18. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.
Gu Q; Zhang B; Sun H; Xu Q; Tan Y; Wang G; Luo Q; Xu W; Yang S; Li J; Fu J; Chen L; Yuan S; Liang G; Ji Q; Chen SH; Chan CC; Zhou W; Xu X; Wang H; Fang DD
Oncotarget; 2015 Aug; 6(24):20160-76. PubMed ID: 26062443
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
J Vet Med Sci; 2022 May; 84(5):666-674. PubMed ID: 35387955
[TBL] [Abstract][Full Text] [Related]
20. The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats.
Li N; Chen B; Lin R; Liu N; Dai HT; Tang KY; Yang JY; Huang YH
Cancer Chemother Pharmacol; 2018 Jan; 81(1):207-216. PubMed ID: 29196964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
